Cardiotoxicity of Immune Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2019.07.141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

2) Lung Cancer Treatment Using Immune Checkpoint Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019English

Risk of Myocarditis in Patients With Cancer Treated With Immune Checkpoint Inhibitors

Chronicles of Oncology
2018English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Review of Cancer Treatment With Immune Checkpoint Inhibitors

Wiener Klinische Wochenschrift
Medicine
2017English

Treatment- And Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

Immune-Related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Anticancer Research
MedicineCancer ResearchOncology
2020English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Patients With Severe Grade Checkpoint Inhibitor Pneumonitis in Non‐small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy